Aardvark Therapeutics (AARD) Asset Writedowns and Impairment (2024)

Aardvark Therapeutics (AARD) reported Asset Writedowns and Impairment of $14000.0 for Q2 2024, down 86.41% sequentially from $103000.0 in Q1 2024.

Aardvark Therapeutics (AARD) Asset Writedowns and Impairment (2024) Analysis & Trends

Aardvark Therapeutics (AARD) has 1 years of Asset Writedowns and Impairment data on file, last reported at $14000.0 in Q2 2024.

For the quarter ending Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $14000.0; the trailing twelve-month figure through Mar 2025 stood at $14000.0 (changed N/A YoY), and the FY2024 full-year result was $117000.0, changed N/A from the prior year.
Asset Writedowns and Impairment eased to $14000.0 in Q2 2024, from $103000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $103000.0 in Q1 2024 to a low of $14000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,561.01 Bn	66,560.72 Bn	-
2	Nanobiotix	1,911.11 Bn	1,911.05 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	467.81 Bn	463.02 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.92 Bn	115.68 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.28 Bn	61.53 Bn	3.31 Bn
7	Belite Bio	62.88 Bn	62.88 Bn	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.53 Bn	34.52 Bn	959.66 Mn
10	Aardvark Therapeutics	143.00 Mn	23.04 Mn	-

Download Data